Table 3. Clinical outcomes reported at the follow-up meetings.

Score	Prolotherapy improvement*			Control improvement*
	Mean±SD	Median†	Min-Max†	Mean±SD	Median†	Min-Max†	Test value	p
VAS (0-21 days)	-1.0±1.2	-1,0	-4.0 to 1.0	-0.7±0.9	-1,0	-2.1 to 1.0	z=-0.996	0,319
VAS (0-42 days)	-2.6±1.2			-1.0±1.7			t=3.700	0,001
VAS (0-90 days)	-3.8±1.8			-1.7±2.5			t=3.255	0,002
VAS (0-360 days)	-4.5±2.4	-4,5	-8.5 to -0.8	-3±2.6	-2,0	-7.5 to 0	z=-2.033	0,042
AOFAS (0-21 days)	6.8±3.8			3.8±9.2			t=-1.116	0,270
AOFAS (0-42 days)	16.9±4.5			4.5±14.3			t=-3.512	0,001
AOFAS (0-90 days)	23.2±7.6			7.6±19			t=-3.367	0,002
AOFAS (0-360 days)	27.6±16			16±16.4			t=-2.358	0,023
FFI (0-21 days)	-4.9±6.3			-2.9±5.2			t=1.203	0,235
FFI (0-42 days)	-19±9.7	-18,91	-40.44 to -0.43	-5.5±11.1	-3,7	-42.25 to 10.44	z=-4.166	<0.001
FFI (0-90 days)	-26.6±13.5	-27,62	-61.31 to -1.74	-9.1±16.4	-3,92	-44.35 to 10.0	z=-3.622	<0.001
FFI (0-360 days)	-31.7±18			-22.6±21.8			t=1.613	0,113
* The change in the outcome scores was used in between group comparison; † The variable doesn’t have normal distribution; SD: Standard deviation; Min: Minimum; Max: Maximum; VAS: Visual Analog Scale; AOFAS: American Orthopedic Foot and Ankle Society Clinical Rating System; FFI: Foot Function Index.